chloroquine has been researched along with Metabolic Diseases in 5 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khunti, S | 1 |
| Khunti, N | 1 |
| Seidu, S | 1 |
| Khunti, K | 1 |
| Schneider, JG | 1 |
| Finck, BN | 1 |
| Ren, J | 1 |
| Standley, KN | 1 |
| Takagi, M | 1 |
| Maclean, KH | 1 |
| Bernal-Mizrachi, C | 1 |
| Muslin, AJ | 1 |
| Kastan, MB | 1 |
| Semenkovich, CF | 1 |
| Klinghardt, GW | 1 |
| Frayer, WC | 1 |
| François, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic Effects of Hydroxychloroquine[NCT02026232] | 21 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to COVID-19 & loss of funding) | |||
| Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome-AIM 2[NCT00455325] | Phase 2 | 35 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
determined by fasting blood glucose performed at baseline and follow-up (NCT02026232)
Timeframe: 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline Glucose (mg/dL) | Follow-up Glucose (mg/dL) | |
| Hydroxychloroquine | 186.9 | 165.9 |
| Placebo | 163.1 | 158.8 |
determined by lipid profile with calculated LDL performed at baseline and follow-up (NCT02026232)
Timeframe: 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline - LDL (mg/dL) | Follow-up - LDL (mg/dL) | |
| Hydroxychloroquine | 90.4 | 72.4 |
| Placebo | 92.8 | 87.7 |
Two techniques were employed: auscultation of seated subjects at rest was performed by a trained observer who recorded the first and fifth phases of the Korotkoff sounds; and, a portable oscillometric device (SpaceLabs Medical) recorded results every 20 min during the day and every hour during the night. Data were analyzed as mean values over 24 hours. (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.
| Intervention | mmHg (Mean) |
|---|---|
| Placebo Comparator: First Intervention (3 Weeks) | 70 |
| Second Intervention (3 Weeks) | 71 |
| Third Intervention (3 Weeks) | 73 |
| Fourth Intervention (3 Weeks) | 73 |
Hepatic insulin sensitivity was measured by comparing glucose production at baseline of zero insulin infusion rate with glucose production at 56 pmol/m2/min. Hepatic insulin sensitivity was expressed as the percent suppression, such that greater percent suppression indicated greater hepatic insulin sensitivity. There are no reference values, since the patients served as their own controls. (NCT00455325)
Timeframe: assessed every 8 - 10 weeks at the end of each treatment period
| Intervention | % suppression inf rate 56 pmol/m2/min (Mean) |
|---|---|
| Placebo Comparator: First Intervention (3 Weeks) | .56 |
| Second Intervention (3 Weeks) | 0.55 |
| Third Intervention (3 Weeks) | 0.66 |
| Fourth Intervention (3 Weeks) | 0.70 |
Fasting Serum Blood Sample (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo Comparator: First Intervention (3 Weeks) | 115 |
| Second Intervention (3 Weeks) | 109 |
| Third Intervention (3 Weeks) | 109 |
| Fourth Intervention (3 Weeks) | 103 |
Fasting Serum Blood Sample (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo Comparator: First Intervention (3 Weeks) | 144 |
| Second Intervention (3 Weeks) | 139 |
| Third Intervention (3 Weeks) | 139 |
| Fourth Intervention (3 Weeks) | 131 |
Two techniques were employed: auscultation of seated subjects at rest was performed by a trained observer who recorded the first and fifth phases of the Korotkoff sounds; and, a portable oscillometric device (SpaceLabs Medical) recorded results every 20 min during the day and every hour during the night. Data were analyzed as mean values over 24 hours. (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period
| Intervention | mmHg (Mean) |
|---|---|
| Placebo Comparator: First Intervention (3 Weeks) | 121 |
| Second Intervention (3 Weeks) | 121 |
| Third Intervention (3 Weeks) | 123 |
| Fourth Intervention (3 Weeks) | 123 |
Fasting Serum Blood Sample (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo Comparator: First Intervention (3 Weeks) | 187 |
| Second Intervention (3 Weeks) | 181 |
| Third Intervention (3 Weeks) | 182 |
| Fourth Intervention (3 Weeks) | 173 |
Fasting Serum Blood Sample (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo Comparator: First Intervention (3 Weeks) | 143 |
| Second Intervention (3 Weeks) | 153 |
| Third Intervention (3 Weeks) | 151 |
| Fourth Intervention (3 Weeks) | 140 |
1 review available for chloroquine and Metabolic Diseases
| Article | Year |
|---|---|
Recent advances in pediatric ophthalmology.
Topics: Child, Preschool; Chloroquine; Eye Diseases; Eye Neoplasms; Herpes Zoster Ophthalmicus; Humans; Infa | 1968 |
4 other studies available for chloroquine and Metabolic Diseases
| Article | Year |
|---|---|
Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19).
Topics: Aged; Cardiovascular Diseases; Chloroquine; Clinical Trials as Topic; COVID-19; Delivery of Health C | 2020 |
ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome.
Topics: Animals; Apolipoproteins E; Ataxia Telangiectasia Mutated Proteins; Atherosclerosis; Cell Cycle Prot | 2006 |
ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome.
Topics: Animals; Apolipoproteins E; Ataxia Telangiectasia Mutated Proteins; Atherosclerosis; Cell Cycle Prot | 2006 |
ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome.
Topics: Animals; Apolipoproteins E; Ataxia Telangiectasia Mutated Proteins; Atherosclerosis; Cell Cycle Prot | 2006 |
ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome.
Topics: Animals; Apolipoproteins E; Ataxia Telangiectasia Mutated Proteins; Atherosclerosis; Cell Cycle Prot | 2006 |
[Lysosomes in experimental storage dystrophy due to chronic chloroquine intoxication (author's transl)].
Topics: Animals; Central Nervous System; Chloroquine; Guinea Pigs; Lysosomes; Metabolic Diseases; Rabbits; R | 1976 |
[Cornea verticillata].
Topics: Benzofurans; Chloroquine; Cornea; Corneal Dystrophies, Hereditary; Eye Diseases; Glycolipids; Humans | 1968 |